fda glp-1 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System GLP-1 Meds Linked to 265
Description
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T
Tip: Please fill out the form if you or a friend would like more information on continuous glucose monitors
Mouse anti-eNOS and anti-phospho-Ser-1177-eNOS (p-eNOS) antibodies were from BD Biosciences (San Joe, CA, USA)
L., Rodbard, H
While the first GLP-1 was approved by the FDA more than 20 years ago, to treat Type 2 diabetes, the use of these drugs took off in 2021 when Novo Nordisk received approval for a semaglutide drug to treat obesity, with the brand name Wegovy
